Results 131 to 140 of about 7,987 (192)

Association between disease awareness and prognosis in patients with glioblastoma: A retrospective cohort study. [PDF]

Medicine (Baltimore)
Wu Y, Xue X, Ji S, Wang W, Tian L, Han X, Su L, Liu J.   +7 more
europepmc   +1 more source

Comments on "Prior Immunotherapy Enhances Survival Outcomes of Third-Line Apatinib Treatment in Advanced Gastric Cancer: A Retrospective Cohort Study". [PDF]

Int J Cancer
Xu H, Lu J.
europepmc   +1 more source

High-sensitivity photoelectric sensing of apatinib for recurrent hepatocellular carcinoma in TACE. [PDF]

RSC Adv
Yang S, Deng Z.
europepmc   +1 more source

Letter: Beyond Survival Benefit in CHANCE2311-Important Considerations in the Interpretation of TACE Combined With Immunotherapy in Advanced HCC. Authors' Reply. [PDF]

Aliment Pharmacol Ther
Ding R.
europepmc   +1 more source

Formic acid released by intratumoral <i>Bacteroides thetaiotaomicron</i> facilitates combinational therapy of Apatinib and aPD-1 in hepatocellular carcinoma. [PDF]

Acta Pharm Sin B
Lu J, Feng F, Li C, Yu Z, Zhang T, Liu A, Gao Q, Li Z, Luo L, Guan X, Xiang Y, Zhuang H.   +11 more
europepmc   +1 more source

Efficacy and safety of camrelizumab plus apatinib in advanced urachal cancer (RUN-SC-0102): a single-arm, multicentre, phase 2 trial in China. [PDF]

EClinicalMedicine
Ju M, Li W, Hu L, Ye X, Yan W, Zhang S.
europepmc   +1 more source

Clinical efficacy and safety outcomes of anlotinib therapy in sarcoma: a systematic review and meta-analysis. [PDF]

J Egypt Natl Canc Inst
Matar H, Melhem A, Shawwa A, Yousef T, Alananbeh M, Alsalim E, Al-Refai E, Abuhwaij M, Elayan D.   +8 more
europepmc   +1 more source

Efficacy and safety of adjuvant low-dose apatinib combined with SOX regimen versus SOX regimen in patients with resectable locally advanced gastric cancer: a cohort study. [PDF]

Front Pharmacol
Wang L, Feng C, Nan Y, Xu Y, Zhang C, Wu W, Duan Y, Zhang H, Zhao Q.   +8 more
europepmc   +1 more source